Effects of Glucoerb® and Epavin® on Cardiometabolic Profile in Adults with Overweight or Obesity: A Three-Month Real-World Study

Background/Objectives: Overweight and obesity are major drivers of cardiometabolic dysfunction and increase the risk of type 2 diabetes (T2DM)and cardiovascular disease. Although lifestyle intervention remains the cornerstone of treatment, complementary strategies may provide additional benefits. The effects of Glucoerb® and Epavin®, administered individually or in combination, on cardiometabolic health in adults with overweight or obesity remain poorly characterized.